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OBJECTIVES: AECOPD is a leading cause of hospitalization.
A valid and easy-to-use risk stratiﬁcation tool applicable not
only for clinical but also economic outcomes would facilitate
population-based outcome studies. We sought to validate an
AECOPD clinical risk stratiﬁcation tool previously reported and
determine its utility for economic outcomes. METHODS: We
analyzed 57,791 AECOPD admissions in 2004–2005 across 191
USA hospitals. The AECOPD risk stratiﬁcation tool identiﬁed
three factors with the highest discrimination of mortality risk:
BUN > 25 mg/dl, Altered mental status, and Pulse > 109 per
minute (BAP). Based on the number of risk factors present on
admission, the BAP classiﬁed patients into four risk categories,
ranging from Low (0 risk factors) to High (3 factors). We exam-
ined mortality, length of stay (LOS), and cost outcomes using the
BAP classiﬁcation algorithm. The cost outcome was calculated
using the Centers for Medicare and Medicaid Services (CMS)
cost/charge ratio for each hospital for a given calendar year.
RESULTS: Overall, median age was 72 (IQR: 63–79) and 55%
were women. Crude mortality was 2.4%. The prevalence for
each of the BAP risk categories was 51.6% (low), 39.7% (Inter-
mediate I), 7.9% (Intermediate II), and 0.8% (High). The corre-
sponding mortality was 1.0%, 2.7%, 8.2%, 17.6%; the mean
LOS was 4.7, 5.4, 6.6, 6.8 days; the mean cost were $5,700,
$6,900, $9,400, $11,400 respectively. The trend-analyses
revealed a graded association between number of BAP risk
factors and worsening outcomes. For every addition of BAP risk
factors, there was an exponential increase in mortality risk (OR:
2.89, CI: 2.70–3.09), 0.81 day increase of LOS (CI: 0.76–0.87),
and $1600 increase of cost (CI: $1500–$1700). P-values for all
trends were <0.0001. CONCLUSIONS: The BAP classiﬁcation
tool accurately differentiates mortality risk. It may also be used
to identify high risk cohorts for prolonged LOS and excess cost
among hospitalized AECOPD patients.
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OBJECTIVE: To determine factors predictive to survival for
patients transferred to respiratory care ward after prolonged
mechanical ventilation. METHODS: We reviewed medical
records in a hospital in southern Taiwan between January 1,
2003 and December 31, 2006 to collect clinical data while trans-
ferred to respiratory care ward. The National death certiﬁcation
database of Taiwan was linked to ascertain the date of death.
Kaplan-Meier estimation was performed for survival analysis;
Cox proportional hazards model was constructed based on
various patient characteristics, including age, gender, education,
co-morbidity with diabetes, stroke, chronic obstructive pulmo-
nary disease, end stage renal disease and blood platelet. A strat-
egy of backward selection was taken. RESULTS: Two hundred
and eighty-seven patients who required chronic mechanical ven-
tilation in intensive care unit were included in this study. Their
median age was 77 years, 56% were male. Survival rate of 90
days and 180 days following transfer to respiratory care ward
were 70 and 50%, respectively. After taking age, gender, and
various co-morbidity into consideration, the adjusted hazard
ratios for end stage renal disease and abnormal blood platelet
count were 1.56 (95% conﬁdence interval (CI), 1.12–2.15) and
1.40 (95%CI, 1.04–1.90), respectively. CONCLUSION: Overall
survival of patients with prolonged mechanical ventilation was
poor, especially for patients with end stage renal disease or/and
abnormal blood platelet count.
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OBJECTIVE: Each year, asthma accounts for 3 million clinic
visits, 550,000 emergency room visits, 150,000 hospitalizations,
and 150 deaths in children under ﬁfteen. Literature suggests that
asthmatic children exposed to tobacco smoke experience com-
plications of greater frequency and severity than those unex-
posed. This study proposes to test the hypotheses that asthmatic
children exposed to household tobacco smoke experience more
frequent and severe exacerbations and have greater inhaler use
than those unexposed. METHODS: NHANES’ 2003–2004 data-
base was queried to identify a cohort of 421 asthmatic children
(ages 0–17) with current diagnosis of asthma and complete
demographic, examination, and questionnaire data. The cohort
was analyzed based on exposure to household tobacco smoke.
Logistic regression was used to examine emergency room (ER)
visit, wheezing frequency, and recent inhaler use. RESULTS:
Results revealed no signiﬁcantly greater frequency or severity of
asthma outcomes in children exposed to tobacco smoke. House-
hold smoke exposure was only signiﬁcantly associated with
inhaler use. Oddly, asthmatic children living in smoking house-
holds were highly unlikely to have used an inhaler in the past
month (Odds Ratio = 0.493, p = 0.0406). Tobacco smoke expo-
sure was associated with higher odds of wheezing attacks, but
lower odds of ER visit (though neither was signiﬁcant). CON-
CLUSION: Despite results, opportunities to improve asthma
outcomes exist. In the sample, children in smoking households
were more likely to be African American, female, live below the
poverty level, and be exposed to other indoor pollutants that
trigger asthma exacerbations. Initiatives targeted to this group
may improve asthma outcomes through education on reduction/
elimination of unnecessary indoor allergens. Study limitations
include small sample size, potential recall bias due to self or
parental-report, lack of data related to family smoking and
asthma history and other exposures, and time variation in data
collection.
RESPIRATORY-RELATED DISORDERS—Cost Studies
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OBJECTIVE: Smoking, a leading cause of morbidity and mor-
tality in the US, results in approximately 440,000 deaths, eco-
nomic costs of $96.8 billion, and losses of more than 5.6 million
years of potential life each year. The aim of this study was to
compare the costs and effectiveness of the new drug varenicline
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against the existing therapy buproprion SR. METHODS: A deci-
sion analytic model was developed using DATA Treeage software
to compare the cost-effectiveness of varenicline with buproprion
SR. The costs and probabilities of success were reported for 12
weeks for 1 mg varenicline and 150 mg buproprion SR. The drug
acquisition costs were obtained from the Drug Topics Red Book
and published clinical trials. The model also included costs and
effectiveness values for placebo. Costs for physician visits and
counseling were obtained from clinical trials and other published
sources. The probabilities of success were reported as the con-
tinuous abstinence rate (CAR) in all the studies. Treatment effects
were compared using head-to-head clinical trials. Incremental
cost effectiveness ratios (ICERs) were calculated for additional
cost/CAR and were estimated relative to placebo. One- way
sensitivity analysis was performed to determine the robustness of
the results. RESULTS: The ICER for varenicline compared to
placebo was $3688/CAR, and the ICER for buproprion SR com-
pared to placebo was $5915/CAR. The total costs of varenicline
and buproprion SR were $1696.2 and $1833.6 respectively.
Varenicline was found to be more effective than buproprion SR
and placebo with a CAR of 0.46, compared to CARs of 0.31 and
0.17 respectively. Sensitivity analysis indicated that the results
were affected by the model assumptions for cost and effectiveness
treatment options. CONCLUSION: Based on the results from
the decision analytic model, smoking cessation therapy with
varenicline should result in lower costs, and higher CARs as
compared to buproprion SR.
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OBJECTIVE: The objective of this study was to assess the cost-
effectiveness of ciclesonide versus ﬂuticasone in adult patients
with mild, moderate, and severe asthma. METHODS: A decision
tree model was developed to simulate the health consequences
and costs associated with daily asthma medication use. Patients
were assumed to receive either ciclesonide or ﬂuticasone. Poten-
tial health consequences for patients in the model included an
adverse drug event (ADE) and symptom-free (SF) day. Costs
included those associated with drug acquisition, the use of rescue
medication, and medical resource utilization due to ADEs or
non-SF days. The efﬁcacy of ciclesonide and ﬂuticasone was
estimated using data from multiple clinical trials and data on ﬁle
at Sanoﬁ-Aventis. Data on medical resource utilization following
ADEs and costs were estimated from published literature. Parity
in the cost of ciclesonide and ﬂuticasone was assumed. The
model was used to calculate total daily costs, probability of an
ADE-free (ADEF)/SF day, and the incremental cost per ADEF/SF
day for ciclesonide versus ﬂuticasone. RESULTS: The use of
ciclesonide is associated with lower costs ($2.01 vs. $2.02) and
higher probability of an ADEF/SF day (0.254 vs. 0.247) than
ﬂuticasone, indicating that ciclesonide dominates ﬂuticasone in
the treatment of patients with varying asthma severity. Results of
a one-way sensitivity analysis of all model parameters suggest
that the model is most sensitive to changes in the probability of
a symptom-free day on treatment with ﬂuticasone. A two-fold
increase in the cost of ciclesonide yields an ICER of $88.38 per
ADEF/SF day. CONCLUSION: Ciclesonide produces more
ADEF/SF days than ﬂuticasone and therefore dominates ﬂutica-
sone when drug prices are equal.
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HEALTH ECONOMICS OF ASTHMA:ASSESSINGTHEVALUE
OF ASTHMA INTERVENTIONS
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OBJECTIVE: We undertook a systematic review of asthma inter-
vention health economic studies from 2002 through 2007, evalu-
ated how well the current health economic recommendations in
asthma have been followed, assessed the implications of health
economics research by comparing ﬁndings to coverage and reim-
bursement patterns and, suggested avenues for future improve-
ment. METHODS: We performed a state-of-the-art review using
multiple search databases. We used past health economic asthma
reviews to assess whether current studies have complied with
previous recommendations. We compared the pharmaceutical
value-for-money conclusions with their formulary coverage from
a large payer in the US and the British reimbursement recom-
mendations. RESULTS: We included 39 of the 176 studies that
met our initial criteria. Data sources used to inform the economic
analyses ranged in duration from 12 weeks (8) to three years (2).
Uncertainty was reported by 19 studies. The most common
beneﬁt outcome was symptom free days (14). Seven studies
reported quality-adjusted life years. Thirty-four of 39 reported
that the intervention of interest was cost-effective or dominant.
CONCLUSION: Previous recommendations for longer-term
pragmatic trials are still germane. Using the Global Initiative for
Asthma guidelines, the reviewed pharmaceutical interventions
assumed relevant comparators but few studies compared combi-
nation products to their collective components. Care should be
taken in the interpretation of incremental cost-effectiveness ratios
that use asthma speciﬁc event avoided outcomes because these
outcomes may not capture the complete effects of treatment and
may be biased due to double counting. We recommend the use of
generic measures sensitive to asthma patients and standardized
across diseases. Willingness-to-pay must be assumed to conclude
cost-effectiveness and must be justiﬁed. The overall ﬁndings from
this health technology assessment review are consistent with
the coverage and reimbursement recommendations in the UK
(British Thoracic Society and Scottish Intercollegiate Guidelines
Network) and US (Aetna’s 2007 preferred drug guide).
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OBJECTIVE: To assess the cost-effectiveness of empirical outpa-
tient treatment options in Canada for community-acquired
pneumonia (CAP) in the presence of antimicrobial resistance.
METHODS: A multi-country decision analytic model to assess
the clinical and economic consequences of antimicrobial resis-
tance, developed for mild-to-moderate empirical CAP outpa-
tient treatment, was adapted to Canada. Treatment algorithms
involved ﬁrst- and second-line treatment in the community, and
incorporated follow-up after treatment failure due to resistance
or other reasons and resulting hospitalizations. Comparators
included (1) ﬁrst-line treatment with azithromycin, a generic
macrolide prescribed in Canada, followed by moxiﬂoxacin, a
ﬂuoroquinolone, and (2) ﬁrst-line treatment with moxiﬂoxacin
followed by azithromycin upon failure. Clinical failure rates with
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